1877 — Shanghai Junshi Biosciences Share News
0.000.00%
Last trade - 00:00- HK$15.67bn
- HK$18.79bn
- CNY2.50bn
Brief: Shanghai Junshi Biosciences Updates On License And Commercialization Agreement With Coherus
Brief: Shanghai Junshi Biosciences Says Approval Of Supplemental NDA For Toripalimab
Brief: Junshi Biosciences's Lock-Up Period For 259.0 Mln A-Shares To End
Brief: Shanghai Junshi Biosciences Says Indications Of Tuoyi & Mindewei Included In National Reimbursement Drug List
Brief: Shanghai Junshi Biosciences Says TGA Accepted New Chemical Entity Application Of Toripalimab
Brief: Shanghai Junshi Biosciences Gets FDA Approval For Marketing Of Toripalimab
Coherus BioSciences jumps after FDA approval of cancer therapy
Brief: Junshi Biosciences Says Q3 Net Loss Of 409.4 Million Yuan
Brief: Shanghai Junshi Biosciences Says Appointment Of Wang Gang As Executive Director Approved
Brief: Shanghai Junshi Biosciences Says Phase III Clinical Study Of Toripalimab Met Primary Endpoint
Brief: Shanghai Junshi Biosciences Announces Entering Into Of Joint Venture Agreement
Brief: Junshi Biosciences Plans To Buy Back A-Share Of The Company
Brief: Shanghai Junshi Biosciences Posts Loss Attributable Of RMB996 Million For Six Months
Brief: Shanghai Junshi Biosciences Approves To Nominate Wang Gang As Executive Director
Brief: Shanghai Junshi Biosciences Plans A-Share Buyback
Brief: Shanghai Junshi Biosciences Says Acceptance Of NDA For Senaparib
Brief: Shanghai Junshi Biosciences Announces Acceptance Of Supplemental New Drug Application
Brief: Shanghai Junshi Biosciences Says Acceptance Of Supplemental New Drug Application For Toripalimab
Brief: Shanghai Junshi Biosciences Says Js207 Injection Received Acceptance Notice For IND Application